Blood-based systems biology biomarkers for next-generation clinical trials in Alzheimer’s disease - Sorbonne Université Access content directly
Journal Articles Dialogues in Clinical Neuroscience Year : 2022

Blood-based systems biology biomarkers for next-generation clinical trials in Alzheimer’s disease

Abstract

Alzheimer's disease (AD)-a complex disease showing multiple pathomechanistic alterations-is triggered by nonlinear dynamic interactions of genetic/epigenetic and environmental risk factors, which, ultimately, converge into a biologically heterogeneous disease. To tackle the burden of AD during early preclinical stages, accessible blood-based biomarkers are currently being developed. Specifically, next-generation clinical trials are expected to integrate positive and negative predictive blood-based biomarkers into study designs to evaluate, at the individual level, target druggability and potential drug resistance mechanisms. In this scenario, systems biology holds promise to accelerate validation and qualification for clinical trial contexts of use-including proof-of-mechanism, patient selection, assessment of treatment efficacy and safety rates, and prognostic evaluation. Albeit in their infancy, systems biology-based approaches are poised to identify relevant AD "signatures" through multifactorial and interindividual variability, allowing us to decipher disease pathophysiology and etiology. Hopefully, innovative biomarker-drug codevelopment strategies will be the road ahead towards effective disease-modifying drugs. .
Fichier principal
Vignette du fichier
Blood-based systems biology biomarkers for%0Anext-generation clinical trials in Alzheimer s disease .pdf (1.15 Mo) Télécharger le fichier
Origin : Publication funded by an institution
Licence : CC BY NC ND - Attribution - NonCommercial - NoDerivatives

Dates and versions

hal-04496053 , version 1 (08-03-2024)

Identifiers

Cite

Harald Hampel, Andrea Vergallo, Mohammad Afshar, Leyla Akman-Anderson, Joaquín Arenas, et al.. Blood-based systems biology biomarkers for next-generation clinical trials in Alzheimer’s disease. Dialogues in Clinical Neuroscience, 2022, 21, pp.177 - 191. ⟨10.31887/dcns.2019.21.2/hhampel⟩. ⟨hal-04496053⟩
10 View
1 Download

Altmetric

Share

Gmail Facebook X LinkedIn More